Figure 2From: Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDsCumulative probability of recurrent ulcer bleeding in patients receiving celecoxib or diclofenac plus omeprazole. Reproduced with permission from [24]. Copyright © 2002 Massachusetts Medical Society. All rights reserved.Back to article page